AVAILABLENot Applicable

Post-Trial Access to ATH434 for Patients With Multiple System Atrophy

Plain-language summary

This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation by their treating physicians.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Completed Alterity protocol ATH434-201 or ATH434-202 * Expected to benefit from treatment from treatment with ATH434, in the opinion of the treating physician Exclusion Criteria: * Discontinued prior ATH434 treatment (ATH434-201 or ATH434-202) for any reason * Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the treating physician's opinion

Trial details

NCT IDNCT07531433

SponsorAlterity Therapeutics

Sponsor typeINDUSTRY

Study typeEXPANDED_ACCESS

Contact for this trial

Alterity Clinical Trials

888-556-7582 clinicaltrials@alteritytx.com

View on ClinicalTrials.gov More Multiple System Atrophy trials